Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients

Sponsor
Sanofi
Study ID
NCT00271271
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Primary: ·To evaluate the activity of the combination of gemcitabine, oxaliplatin and vinorelbine as first line treatment in patients with non-small cell bronchopulmonary cancer Secondary: ·To evaluate the toxicity of the combination

Key Dates

First listed
Dec 30, 2005
Start date
Jun 30, 2003
Status verified
Dec 2009
Completion
Oct 31, 2006

Study Design

Enrollment
40 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Objective rate of response (ORR) according to the RECIST criterion, as evaluated by a review panel of outside experts.

Related Studies